Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study

Table 3 Results of early post-discharge phase analysis

	SGLT2i (N = 818)		Non-use (N = 28,472)		Crude HR (95% CI)	Weighted HR^‡ (95% CI)
	Events	IR ^†	Events	IR ^†	Crude HR (95% CI)	Weighted HR^‡ (95% CI)
At 30 day
Composite outcome	57	88.5	2,199	98.6	0.90 (0.69–1.17)	0.74 (0.69–0.79)
HF readmission	56	87.0	2,155	96.7	0.90 (0.69–1.18)	0.74 (0.69–0.79)
Cardiovascular death	2	3.0	98	4.2	0.71 (0.18–2.87)	0.58 (0.42–0.81)
At 60 day
Composite outcome	77	61.2	3308	76.6	0.81 (0.64–1.01)	0.82 (0.78–0.86)
HF readmission	74	58.8	3228	74.7	0.79 (0.63-1.00)	0.81 (0.77–0.85)
Cardiovascular death	4	3.0	194	4.2	0.72 (0.27–1.93)	0.56 (0.44–0.72)
At 90 day
Composite outcome	95	51.3	3,980	62.9	0.82 (0.67–1.01)	0.84 (0.80–0.88)
HF readmission	91	49.1	3,877	61.2	0.81 (0.66-1.00)	0.81 (0.77–0.85)
Cardiovascular death	7	3.5	263	3.8	0.93 (0.44–1.96)	0.96 (0.80–1.16)

† The number of events per 100 person-years
‡ Inverse probability of treatment weighting on the propensity score with asymmetrical trimming was used to balance comparison groups on indicators of baseline characteristics. This method produced a weighted pseudo sample of patients in the exposed and reference group with the same distribution of measured covariates
Abbreviations: CI, confidence interval; HF, heart failure; HR, hazard ratio; IR, incidence rate; SGLT2i, sodium-glucose co-transporter 2 inhibitor

ISSN: 1475-2840